PT-141 (Bremelanotide) Research Overview

Overview

PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that functions as a melanocortin receptor agonist. Unlike earlier melanocortin analogs, PT-141 was specifically developed to investigate the role of melanocortin signaling in sexual function, with a primary focus on MC3R and MC4R receptor subtypes.

The PT-141 molecule is a cyclic peptide with structural modifications that confer enhanced metabolic stability and receptor selectivity compared with natural α-MSH. It activates melanocortin receptors, including MC3R and MC4R, which are expressed in central nervous system regions involved in the regulation of sexual function and appetite. The peptide's structure is similar to that of MT-2 but with modifications that alter its receptor selectivity profile.

Laboratory and human clinical studies have examined PT-141 for its effects on sexual function through its action on the hypothalamic-pituitary-gonadal axis and central melanocortin pathways. Research has investigated its potential to influence sexual arousal and function in both male and female populations. The peptide's effects are believed to be mediated through activation of central melanocortin pathways involved in sexual behavior.

PT-141 has been evaluated in human clinical trials for specific indications, with published findings from controlled studies examining its effects on sexual function under various study conditions. Research has reported effects on sexual arousal and function in specific populations, although findings have varied across different study designs and outcome measures.

The peptide has been investigated for its effects on other melanocortin-mediated processes, including appetite regulation and skin pigmentation. However, its primary research focus has been on sexual function, and other effects have been examined primarily in the context of understanding its broader pharmacological profile.

Key Scientific Characteristics

Synthetic cyclic heptapeptide analog of α-MSH

Melanocortin receptor agonist with activity at MC3R and MC4R

Developed to investigate melanocortin signaling in sexual function

Cyclic structure confers enhanced metabolic stability

Human clinical studies have been conducted evaluating its effects on sexual function

Not approved for all potential research applications by the U.S. Food and Drug Administration

Research Notes

PT-141 has been investigated in clinical research for its effects on sexual function through melanocortin receptor signaling. Studies have examined its pharmacological properties, biological activity, and safety profile across different study populations.

Ongoing research continues to investigate the mechanisms through which melanocortin receptor activation influences sexual function and other physiological processes. Additional studies are needed to further characterize its applications in sexual function research and related areas.